Purpose: At least 50% of IBD patients do not respond to 6-mercaptopurine(6-MP) and azathioprine(AZA). Many of these patients have (high) normal thiopurine methyltransferase (TPMT) activity and preferentially metabolize 6-MP to 6-methylmercaptopurine(6-MMP) instead of the active metabolite 6-thioguanine(6-TGN). The aim of this report is to describe the use of allopurinol, which competitively inhibits xanthine oxidase (XO), as a therapeutic adjunct in 6-MP/ AZA non-responders to deliberately shunt metabolism of 6-MP towards the active metabolite 6-TGN.
Results: Baseline IBDQ and SF-36 scores were similar among groups. The baseline mean total IBDQ score was 126. The baseline mean physical and mental component summary scores (PCS = 39 and MCS = 41) of the SF-36 were ∼1 standard deviation below the general U.S. population means (50), indicating impaired HRQL. At wk 8 and wk 30, the combined IFX group had greater improvements (p < 0.001, Table 1 ) from baseline in total IBDQ, PCS, and MCS scores vs PBO. All 4 IBDQ dimensions had improvements in the combined IFX group vs PBO (p < 0.001), at both time points. All 8 scales of the SF-36 showed improvement in the combined IFX group vs PBO at both timepoints, with significance (p < 0.05) in all but one scale at wk 30 (role-emotional, p = 0.081). There were no notable differences between the trials or the IFX groups. Compared to Placebo: a-p < 0.001; b-p < 0.01; c-p < 0.05; d-p = 0.066.
Conclusions: IFX 5mg/kg or 10mg/kg results in substantially improved HRQL vs PBO, as measured by both disease specific and generic instruments. * Gastroenterology, Brigham and Women's Hospital, Boston, MA and Gastroenterology, Children's Hospital, Boston, MA. Purpose: Small uncontrolled trials have suggested that 5-aminosalicylate (5-ASA) medications increase 6-thioguanine (6-TG) nucleotide levels in adults with Crohn's disease (CD) on azathioprine (AZA) or 6-mercaptopurine (6-MP), presumably through the inhibition of thiopurine methyltransferase (TPMT). We tested the theory that co-administration of 5-ASA agents with AZA or 6-MP results in higher levels 6-TG in a large cohort of children and adults with CD or ulcerative colitis (UC). Methods: In this retrospective cohort study, we identified all children and adults treated with AZA or 6-MP for IBD at two institutions. Patients were included if TPMT genotype was known and 6-TG and 6-methylmercaptopurine (6-MMP) levels had been tested after at least 3 months of clinical remission at a stable dose of 6-MP or AZA. Remission was defined as a Harvey-Bradshaw score < 4 (CD) or Mayo score < 3 (UC) in the absence of steroids, infliximab, or other immunomodulators. 6-MP dosage (mg/kg) was determined for each patient, using standard conversion factor for AZA (2.07). 6-TG and 6-MMP levels were compared between patients taking a 5-ASA medication and those who were not. Linear regression was used to evaluate and adjust for potentially confounding variables. Results: 120 patients were included, with median age 21 (range 6-79). 65 (54%) patients were male. 94 (78%) had a diagnosis of CD, 26 (22%) had UC. 84 (70%) were taking a 5-ASA medication (median dose 51mg/kg, range 25-87 mg/kg). 111 (92%) were TPMT genotype +/+ and 9 (8%) were TPMT ±. Patients on a 5-ASA agent had a significantly higher mean 6-TG level compared with those who were not (248.2 vs 195.7 pmol/8 × 10 8 RBCs, p = 0.0248) despite comparable mean 6-MP dosage (1.12 vs 1.16 mg/kg, p = 0.6358). This difference remained significant when adjusted for IBD type and TPMT genotype (p = 0.0122). Age, gender, institution, and choice of AZA/6-MP had no effect on mean 6-TG levels (all p-values > 0.1). No association was seen between 5-ASA therapy and median 6-MMP level (2248.5 vs 1781 pmol/8×10 8 RBCs, p = 0.33). Conclusions: 5-ASA therapy is associated with higher mean 6-TG levels in children and adults with UC or CD in remission on AZA or 6-MP. These data suggest that 5-ASA medications can be used with AZA or 6-MP to increase 6-TG levels. 5-ASA agents may be helpful in patients who are 6-MP refractory due to preferential metabolism towards the 6-MMP pathway. Purpose: Crohn's disease (CD) perianal fistulas can cause significant morbidity including fecal incontinence. The rate of fecal incontinence in these patients (pts) varies in the literature. The purpose of this study was to assess the rate of fecal incontinence in pts with CD perianal fistulas and to determine if there is a difference in outcomes between those pts who have undergone primarily medical or surgical treatment for their perianal disease Methods: The medical records of pts who presented to the GI Clinic at a single academic medical center between 1/01 and 1/04 with perianal CD were reviewed. Demographic data and information regarding treatment was recorded. Mailed questionnaires and telephone interviews were conducted to determine the Fecal Incontinence Severity Index (FISI) score and patient satisfaction.
Results:
Of 77 pts identified with CD perianal fistulas, a total of 40 (52%) completed the questionnaire. 25 (63%) pts had surgical treatment while15 had medical treatment only. The baseline demographic data was similar in both groups. The overall rate of fecal incontinence was high with 64% of all pts having ≥ 1 episode a week of solid stool incontinence. There was no difference between the medical and surgical cohorts (67% vs. 60%; p = .75) The median FISI for the medical group was 37, (range 0 -59) while the median FISI for the surgical cohort was 33 (range 4-56; p = .54). The type of surgical treatment did not affect outcome. Surgical pts who had less invasive operations (incision and drainage or seton placement) had a median FISI of 31, and pts who underwent more aggressive surgical treatment (fistulotomy, fistulectomy, or advancement flap) had a median FISI 42 (p = .52). Surgical pts were asked to rate their degree of satisfaction (1 = poor and 5 = excellent). Pearson's product moment analysis revealed there was not a strong relationship between level of satisfaction and FISI score (correlation = .06, p = .78) Conclusions: The rate of fecal incontinence in pts with perianal CD is high. There is not a significant difference in the degree of fecal incontinence between pts treated medically or surgically for perianal CD, nor is there a significant difference in fecal incontinence with the different surgical procedures. Surgical pts with higher FISI scores are not necessarily less satisfied with their surgical results
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Osteonecrosis Crohn's disease patients (52% male). Median age at AVN diagnosis (dx) was 45.9 years (yrs) (range, 16.5-82.2), and median duration from IBD to AVN dx was 9.2 yrs (0.5-41.2). Of all 94 pts, only 6 pts (6%) had no history of systemic corticosteroid exposure. Steroid-naïve IBD-AVN pts were older at both IBD dx (51.8 yrs) and AVN dx (67.3 yrs) than steroid users. All 88 steroid users had received oral corticosteroids, and 26 had also received IV steroids (24%). Among pts with available data, median cumulative duration of steroid therapy prior to AVN dx was 12.2 months (range, 2-70.2), median daily prednisone dose was 20.4 mg (12.1-50), and median cumulative prednisone dose was 9,205 mg (2, 660) . Overall, 41% had a prior arthropathy and 40% had a history of smoking, with similar rates for those with and without corticosteroid use. The mean number of joints involved was 2.3 among those who had received steroids (55% femoral head, 23% upper extremities) versus 1.2 among those who had not (57% femoral head, 0% upper extremities). The prevalence of stage III-IV AVN was 77% in steroid users versus 67% in the steroid-naïve. Median follow-up time after AVN dx was 4.4 yrs (0-27.3). Treatment included arthroplasty in 36%, conservative therapy in 20%, core decompression in 10%, and bone grafting in 7%. Despite treatment, 16% of pts developed worsening symptoms, and 17% had AVN involvement of new joints-none of this progression was seen in the 6 steroid-naïve pts. Conclusions: Osteonecrosis is a rare but serious complication seen in IBD. In a minority of pts, AVN may occur in the absence of corticosteroid therapy. These pts are older at IBD and AVN dx, have fewer joints involved, and have less progression of the joint disease. Purpose: Optimal medical management of Crohn's disease has long been a challenging process. Currently, it is common practice to "stack" medications to induce remission by starting with the less toxic 5-aminosalicylic acid, then adding Azathioprine or 6-mercaptopurine and finally Infliximab. Concomitant immunosuppressive therapy is employed to reduce the magnitude of the immunogenic antibody response to Infliximab so as to enhance its medical efficacy Results: 14 CD patients had p53 IHC staining of colon (13) or ileum (1). p53 mutations were found in 8 patients (p53+) and were absent in 6 patients (p53-). 7 out of 8 p53+ patients had histologic evidence of dysplasia (6 with low-grade dysplasia (LGD), 1 with high-grade dysplasia (HGD)) while only 1 out of 6 p53-patients had dysplasia (LGD) (p = 0.03). There was no significant difference between the two groups in gender (female: 6/8 vs. 4/6; p = NS), mean age of onset of CD (27.1 y vs. 27.7 y; p = NS) or in the mean duration of disease at the time of p53 staining (17.0 vs. 17.0; p = NS). In each group, four patients had subsequent surveillance exams or surgical resections. In the p53+ group, 2 out of 4 patients progressed from LGD to HGD after 0.5 y and 2.25 y, respectively, and were referred for partial colectomy. In the p53-group, 3 patients without dysplasia on initial biopsy did not progress to dysplasia after 1 y, 1 y, and 7 y, respectively. The one p53-patient with LGD on initial biopsy underwent colectomy and had no evidence of dysplasia in the surgically resected specimen. Conclusions: p53 mutations in CD patients are associated with dysplasia in this population and may predict progression to a higher grade of dysplasia over time. Testing for p53 mutations may aid in stratification of CD patients at risk for CRC. This research was funded in part by Proctor & Gamble. Philip Miner, Jr., M.D., Sander van Deventer, M.D., John Su, Ph.D., Mark Wedel, M.D., Emil Chuang, M.D. * G.I., Oklahoma Foundation for Digestive Research, Oklahoma City, OK; G.I., Academic Medical Center, Haarlem, Netherlands and Clinical, Isis Pharmaceuticals, Inc., Carlsbad, CA. Purpose: A high placebo rate has been observed in previous IBD trials. Some have suggested that patients with mild baseline disease activity may increase the background "noise" and negatively impact the efficacy data. Positive data from two alicaforsen Phase 2 studies were recently presented, one placebo controlled and one with an active control, mesalamine (CS22). In the placebo controlled study (CS27), 112 subjects were randomized to compare 4 alicaforsen dose/schedules compared with placebo. Consistent with the CS22 results, CS27 study showed that 6 wks of 240mg alicaforsen qhs enema resulted in a durable clinical response that was statistically significant from placebo at Wks 18 and 30, (p = 0.04 and 0.03). To optimize the probability of success in Phase 3, we must understand the impact mild UC patients have on the efficacy data. Methods: Data from 44 subjects in the highest alicaforsen dose and placebo groups were reanalyzed to include only the subjects with moderate disease (DAI ≥ 7). Results: Eleven subjects met the criteria for moderate disease. Fig. A shows the high placebo response phenomenon commonly described in UC trials. Although the study demonstrated statistical difference at Wks 18 and 30, the study did not demonstrate a statistical difference at Wks 6 and 10 (p = 0.17 and 0.26). However, the placebo response was virtually eliminated when only patients with moderate disease were analyzed (Fig. B) , without affecting the response curve of alicaforsen. Statistical difference was demonstrated at Wks 6 and 10 (both p = 0.05), even with a small number of patients.
Conclusions:
The sub-analysis confirms previous trial experience that inclusion of patients with mild baseline UC may significantly impact the placebo response rate and therefore has the potential to impact the outcome of the study. Careful consideration should be given in future studies to exclude patients with mild baseline disease activity. Purpose: Three teenage patients, previously diagnosed with gastrointestinal Crohn's disease developed severe pulmonary symptoms requiring hospitalization. The Purpose of this investigation is to describe the clinical outcome of their pulmonary disease following treatment with Infliximab. Methods: All three patients had their gastrointestinal symptoms well controlled on combinations of medical therapy that included 6-mercaptopurine, mesalamine, and/or steroids. All 3 patients had chest x-rays that showed diffuse pulmonary infiltrates. One patient had a left-sided pleural effusion. Results: CT scans confirmed the radiographic findings. Open lung biopsies in 2 patients showed non-necrotic, non-caseating granulomas consistent with pulmonary Crohn's disease. The other patient had evidence of organizing pneumonia. The 2 patients with pulmonary granulomas were treated initially with infliximab (5 mg/kg) that resulted in rapid improvement of respiratory symptoms within 3 days. The patient with organizing pneumonia was treated with high-dose steroids and intravenous broad spectrum antibiotics and after 2 weeks showed no significant improvement. He was subsequently treated with infliximab (5 mg/kg) that resulted in an equally rapid improvement of his respiratory symptoms. All patients were discharged from the hospital within 3 days of these infusions and all received repeat infliximab infusions at 2 and 6 weeks following the initial infusion and every 8 weeks thereafter. At the present time the follow-up, which ranges from 1 to 18 months, has shown all 3 patients to be free of all respiratory symptoms. Conclusions: Pulmonary involvement, rarely reported in the pediatric population, has been identified in patients with Crohn's disease. Infliximab therapy, which is well-tolerated, may be the drug of choice for these patients. (2), reduction of abdominal mass (1), and treatment of pyoderma gangrenosum (1). IFX 5mg/kg was administered on admission after negative PPD. Sixteen patients that received IFX were matched to 16 who received hydrocortisone based on a similar goal of therapy. Response was measured by the CCFA-IOIBD score on days 0, 3, 5 and at discharge for patients in the two groups. Admission IOIBD score for the IFX and hydrocortisone group were 13.5(4.4) and 17.8(7.1) respectively. Clinical response guided by that score coincided with a 50% reduction in the score. Patients were discharged at the physician's discretion when the established goal was achieved.
Results: It was observed that there was no difference in regard to response to treatment during hospitalization between the two groups. On average, the IFX group showed clinical response by 4 ± 2.6 days. This coincided with a mean score of 7 ± 3 or a 48% reduction in the CCFA-IOIBD score, while the hydrocortisone group showed clinical response by 8.4 ± 2.6 days with a mean score of 6 ± 3.2 or a 66% reduction by discharge. Purpose: We evaluate the indications for infliximab to treat pediatric ulcerative colitis (UC) and report long-term follow-up. Methods: The charts of 27 pediatric patients with UC who were treated with infliximab were reviewed. All patients would have otherwise been candidates for colectomy. The acute group included patients with new onset UC refractory to IV steroids for 5-7 days and patients with non-steroid dependent UC with a fulminant exacerbation; the chronic group included patients with chronic steroid dependent UC. Lichtiger colitis activity index (LCAI) was measured for all patients at 0, 1, and 2 months after infliximab. Patients were regarded as successfully treated if they remained off steroids and avoided colectomy.
Results:
The acute and chronic groups included 16 and 11 patients respectively. The acute group had a mean LCAI score of 11.4 at induction and a mean net change of 11.1 after 2 months. The chronic group had a mean LCAI score of 11.2 and a mean change of 5.7. The acute group had a significantly greater net LCAI change than the chronic, p = 0.001. The net LCAI change in the patients treated successfully was not significantly different than those who failed, p = 0.43. The mean follow-up time from last infliximab was 13 months. Infliximab was successful in 75% of patients in the acute group and 27% in the chronic. Infliximab is no longer required in 80% of patients (83% of acute; 67% of chronic) who were successfully treated. These patients had a mean of 10 infusions and a mean follow-up of 10 months from last infliximab. A CT scan of head and neck revealed a large retropharyngeal abscess that was surgically drained. Empiric anti-biotic coverage was initiated, pending blood and abscess cultures. Tracheostomy was performed on fourth post-operative day to facilitate weaning from mechanical ventilatory support. A subsequent episode of massive hematochezia prompted an emergent colonoscopy, which revealed a blood filled colon and deep "punched-out" ulcers throughout the proximal ascending colon with evidence of recent bleeding. Patient underwent a right hemicolectomy for massive persistent bleeding. Gross surgical pathology showed areas of superficial ulcerations, and transmural chronic inflammatory changes consistent with crohn's disease. Six days after the tracheostomy the formation of a fistula tract was noted at the lower part of the tracheal stoma. The patient was treated with oral steroids and mesalamine for both the colitis and fistulizing process and did well. Discussion: When compared to enteral crohn's disease, pulmonary involvement is much less common and therfore potentially under-diagnosed. Pulmonary involvement of Crohn's disease is notable for mucosal inflammation of the tracheo-bronchial tree, pulmonary parenchyma, or pleuralcoetaneous fistula at the tracheostomy site as a consequence of bronchopulmonary crohn's disease. Primary symptomatology includes cough, hoarseness, wheezing, mucopurulent sputum and possibly upper airway obstruction characterized by stridor. The patient we describe here reported non-specific symptoms of both a chronic systemic inflammatory disease and chronic bronchitis culminating in airway obstruction. In summary we report a rare case of crohn's disease initially presenting as a life threatening retropharyngeal abscess. Purpose: There are contradictory data in the literature regarding the effect of anti-TNF agents on the apoptosis of leukocytes. This is the first study to compare the effect of the anti-TNF agents etanercept, infliximab, adalimumab, and certolizumab pegol on the induction of apoptosis directly in vitro in normal activated lymphocytes and monocytes. Methods: Leukocytes were stained in whole blood with the directly fluoresceinated anti-TNF reagents or relevant controls and analyzed by flow cytometry after isotonic lysis of red cells. Peripheral blood mononuclear cells were prepared using density gradient centrifugation. Lymphocytes were then isolated from this population by negative selection and monocytes by positive selection using MACS beads. Lymphocytes were cultured with anti-CD3 and anti-CD28 for 24 hours and the monocytes with IL-4 and GMCSF. The effect of the anti-TNF agents on apoptosis of these cells over this period was determined by Annexin V binding using flow cytometry.
Results: All four anti-TNF agents bound to peripheral blood neutrophils, monocytes, and a subset of lymphocytes in comparison with negative control reagents. Infliximab, adalimumab, and etanercept were equally potent at causing apoptosis of the activated monocytes and lymphocytes in this system. Certolizumab pegol did not mediate apoptosis of any cells above the level of the negative control.
Conclusions:
This study confirms the data in the literature regarding the induction of apoptosis of activated monocytes and lymphocytes in vitro by infliximab and adalimumab. However in our system, etanercept was found to mediate mononuclear cell apoptosis in a similar manner to infliximab and adalimumab, which contradicts other published reports. Therefore, our study indicates that the exact conditions used for in vitro experiments may significantly affect the results obtained. These data also raise the possibility that the lack of efficacy seen with etanercept in Crohn's disease is not owing to an inability to cause apoptosis. Certolizumab pegol is the only anti-TNF agent that, under the conditions tested, does not kill leukocytes in vitro by apoptosis.
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In Purpose: To determine the ability of the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol to kill cells expressing membrane TNF by complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).
Methods: NS0 cells transfected with human TNF (TNF 6.5 cell line) were used for this study. These cells express high levels of membrane TNF on their cell surface. Directly fluoresceinated reagents were used to determine the level of binding of the anti-TNF agents compared with negative control reagents on the TNF 6.5 cell line by flow cytometry. CDC of the TNF 6.5 cell line by the different reagents was determined by measuring lactate dehydrogenase release from the cells and by measuring propidium iodide (PI) staining using flow cytometry. ADCC was performed on the TNF 6.5 cells using monocyte-depleted peripheral blood mononuclear cells as the effector cells. Cell killing was also quantified using PI staining measured by flow cytometry.
Results: All four anti-TNF agents bound to the membrane TNF on the TNF 6.5 cells, although etanercept bound to a lesser degree than the other reagents. However, CDC and ADCC of TNF 6. Purpose: Endoscopy is frequently performed to assess activity and extent in active ulcerative colitis (UC). However, endoscopy correlates poorly with activity and may not influence treatment in UC.We tested the hypothesis that therapy for active UC can be based on clinical grounds without the need for endoscopy. Methods: Retrospective analysis of 100 consecutive outpatients with clinically active UC who underwent endoscopy. Investigator blinded to endoscopy result predicted therapy based on clinical disease activity (partial Mayo score), gross extent at previous colonoscopy and current medications. Partial Mayo score(stool frequency,rectal bleeding and physican global assessment) classified activity as mild, moderate or severe. Predicted therapy was either maximizing mesalamine or corticosteroids/surgery. Maximizing mesalamine was increasing oral mesalamine (Asacol≥3.6g, Colazal≥6.75g, Pentasa≥3g, sulfasalazine≥4g) and/or adding topical mesalamine. Activity (endoscopy component of Mayo Score) and extent based on current colonoscopy, actual treatment and response by 6 months were recorded.
Results: Clinical criteria were more accurate for predicting maximizing mesalamine therapy compared to corticosteroids/surgery (p < 0.001). Of the 78 patients we predicted maximizing mesalamine therapy, 74 (95%) received this therapy after endoscopy. Of the 4 given steroid therapy,3 had flared after a recent steroid taper. Of the 22 patients we predicted corticosteroids/surgery,15(68%) received this therapy. Of the 7 who did not, colonoscopy showed less extensive disease compared to previous colonoscopy in 2, quiescent disease in 1, less activity compared to partial Mayo score in 1 and in 3,steroids were withheld because of patient/physician preference. Adjusted accuracy for corticosteroids/surgery was 82% (18/22). Endoscopy demonstrated a poor correlation (coefficient = 0.54, p < 0.001)with clinical activity.Response rates for mesalamine and corticosteroids were 87 and 59% respectively. Conclusions: Clinical criteria are accurate to begin treatment among patients on suboptimal mesalamine therapy. However, in 20% patients where corticosteroids/surgery was predicted, endoscopy resulted in avoidance of this therapy. Purpose: The objective of this study was to assess whether 18 fluorodeoxyglucose (FDG) positron emission tomography combined with computerized tomography (PET/CT) would serve as a non-invasive test for evaluation of disease activity in IBD.
Methods:
We studied 10 patients with active Crohn's disease (CD) or ulcerative colitis (UC). There were 7 males and 3 females. All 7 patients with CD had a Crohn's Disease Activity Index greater than 250 and 3 patients with UC had an Ulcerative Colitis Disease Activity Index of greater than 8 (scale 0-12). All patients underwent a PET/CT scan using a GE Discovery LS PET/CT scanner with sequential CT scanning in 10 and a full CT enterography in 4. PET/CT scans were read by an evaluator blinded to the clinical information. Results were scored according to five regions: small intestine and ascending, transverse, descending and rectosigmoid colon. A score of 0-3 was assigned to each region. Activity less than or equal to liver was considered grades 0 and 1, activity of 3 times the liver or greater being grade 3 and grade 2 being intermediate. A score of 0-1 was interpreted as inactive disease while 2-3 was considered active. Clinical disease activity (by findings from colonoscopy, small bowel imaging, current or previous CT scan) was assessed using the same regional analysis.
Results: PET/CT scan showed activity in 45 of 50 possible regions with CT being very helpful in identifying anatomy. In 36 regions, PET activity correlated well with clinical activity (16 inactive, 20 active). In 7 of 10 patients, there were 4 or more regions of correlation of disease activity with the average number of correlating regions in all 10 patients being 3.6. PET appeared to be more sensitive for identifying inflammation with 11 regions showing PET activity and clinical inactivity, and 3 regions showing clinical activity and PET inactivity. Conclusions: PET/CT scan is a novel and non-invasive method to quantify disease activity in patients with IBD. Future studies to assess its clinical role in diagnosis and management of patients with IBD are needed. Purpose: Controversy exists regarding whether use of nonsteroidal antiinflammatory drugs (NSAIDs) is associated with flare of Crohn's disease (CD) and ulcerative colitis (UC). The aim of this study was to examine the association between prescription NSAID use and exacerbation of CD and UC. Methods: We used data from the General Practice Research Database (GPRD) from 1988 to 1997 to conduct a case-crossover study. We used our previously validated algorithm to identify periods of remission and identification of new flares of disease (Gastroenterology 2004; 126:665) . Start of remission periods were identified if there was no prescription for corticosteroids (CS) or 5-aminosalicylic acid (5-ASA) for > 122 days. Newly diagnosed flares were identified by a new prescription for CS or 5-ASA following a remission period. We randomly selected one date during each remission period and the first date of each new flare. Use of NSAIDs was defined as receipt of a prescription within the preceding 60 days. Secondary analyses explored shorter time windows and more than one prescription. Conditional logistic regression was used to assess the association between NSAID use and flare of disease. Adjusted models included use of aspirin, antibiotics, azathioprine/6MP, season of the year, and calendar year as potential confounders. Results: Response rate was 85% (n = 169; Crohn's-113; ulcerative colitis-47; indeterminate colitis-9). Median age was 35 years (range 13-75). Over 80% saw a primary care doctor at least annually. Risk factors for viral hepatitis were found in 75 patients but only 32% of these had received HBV vaccination. Risk factors included transfusions (n = 59), tattoos (23), chronic liver disease (4), dialysis (2). Six of 9 vaccinated patients who were tested had no surface antibody; 1 had active HBV infection. Most (n = 155) reported current or prior use of immunosuppressive medications; 31% of these routinely get flu shots and 8% have had pneumococcal vaccine. Reasons for not getting a flu shot include "didn't know I need it" (53%) and "afraid of side effects" (19%). Over 50% did not recall a tetanus shot within the past 10 years. Thirty-one (18%) could not recall chicken pox infection; 12 of these had varicella vaccination. Four were found to be serologically naïve. Purpose: Patients with ulcerative colitis (UC) or Crohns colitis (CC) have an increased risk of developing colorectal cancer (CRC). There are limitations to surveillance colonoscopy including compliance issues and sampling error. Therefore, we performed this pilot study to examine the utility of stool DNA-based assays in detecting neoplastic lesions in patients with UC or CC. Methods: DNA from stool samples collected from 13 UC patients and 3 CC patients, M/F ratio: 10/6, mean age: 50.1 years (range: 26-81), mean duration of illness: 19.6 years (range: 1-45 years) was extracted, amplified with PCR and analyzed for 21 mutations within the K-ras, APC and p53 genes, deletions in BAT 26 and for DNA integrity (DIA). DIA identifies long DNA strands (1300-2400 bps, non-apoptotic DNA), which are distinct from shorter strands (200 bps) that develop as a result of normal programmed cell death. DNA results were correlated with the pathologic findings in either the patients biopsy (n = 5) or resection (n = 11) specimens. Results: Of the 16 patients, 5 had CRC, 5 had flat low-grade dysplasia (LGD), 1 had polypoid LGD and 5 patients had no evidence of dysplasia or carcinoma (Ca) on surveillance colonoscopy (3) or colectomy (2). Overall, 11/11 study patients with dysplasia or Ca had a molecular abnormality compared to only 2/5 (40%) controls (P = 0.018). The DIA assay was positive in 7/11 (64%) patients with either previous or current dysplasia or Ca compared to 2/5 (40%) control patients without dysplasia/Ca. K-ras mutations were detected in the four DIA negative patients with either flat (K12p2, K13p2) or polypoid LGD (K13p2) or cancer (K13p2, K12p1) in their colectomy specimens but in none of the 5 control patients. None of the patients had mutations in APC or p53 or deletions in BAT 26. Conclusions: Evaluation of DNA mutations and alterations in stool is a promising new technique that may serve as a useful adjunct to colonoscopic surveillance for the detection of dysplasia or Ca in patients with IBD. Larger studies are needed to determine the sensitivity and specificity of this surveillance approach. Purpose: Ileal pouch-anal anastomosis (IPAA) has become the surgical treatment of choice in patients ulcerative colitis (UC) & familial adenomatous polyposis who require surgery. Persistent iron deficiency anemia without overt GI bleeding can occur after IPAA. The identification of etiologic factors can be challenging. Wireless capsule endoscopy (WCE) may provide a useful tool to assess small bowel mucosal diseases but its role in patients with IPAA has not been studied. Our aim was to compare diagnostic role of EGD/pouch endoscopy with small bowel histology and WCE in IPAA patients with persistent iron deficiency anemia. Methods: Seven patients with IPAA who had iron deficiency anemia (Hb < 10) > 12 months after IPAA that persisted > 12 months were enrolled in the study. The patients who had obvious contributing causes of iron deficiency anemia such as persistent hematochezia or heavy menstrual periods were excluded. EGD with small bowel biopsy and pouch endoscopy with neo-terminal ileum, pouch, and cuff biopsy, and serology for celiac disease were performed. WCE was administered after partial small bowel obstruction was excluded based on clinical, endoscopic, and radiographic evaluation. Final diagnosis of the etiology of anemia was based on a combined assessment of clinical, laboratory, endoscopic, and histologic data.
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Results: A total of 7 patients included 4 females (57%) with mean age 39.3 ± 17.6 years, mean time since IPAA 4.8 ± 5.0 years. 6 patients had underlying UC and 1 had juvenile polyposis. Five patients had active pouchitis and 2 had normal pouches on pouch endoscopy. None of the patients regularly used NSAIDs. WCE was administrated in all 7 patients with successful passage. Mucosa of small intestine was adequately visualized. The cause of iron-deficiency anemia was identified in 4 patients (57%) -3 patients (43%) by WCE and 2 patients (29%) by EGD, pouch endoscopy, and small bowel histology (P > 0.05). was not counted as a subsequent surgery. The cumulative incidences of proctocolectomy from time of diagnosis and subsequent surgeries from time of colectomy were estimated using the Kaplan-Meier method.
Results:
The 378 incidence cases of UC (56.1% male) were followed for a total of 6,360 person-years (median follow-up per patient, 15.1 years; range, 0.1 -58 years). Eighty-one (21%) underwent a surgical procedure for UC, of whom fifty-six (69%) underwent more than one procedure. See table for actuarial rates of colectomy and post-colectomy surgeries (95% CI). In those undergoing proctocolectomy with Brooke ileostomy, the cumulative risk of stomal revision was 17% at year 10 and 27% at year 20, and cumulative risk of a stomal hernia repair was 9% at year 10 and 20% at year 20. The cumulative risk of any subsequent surgery in patients with Brooke ileostomy at year 10 was 39%, versus 53% among IPAA patients. The cumulative risk of conversion to permanent ileostomy or diverting ileostomy in IPAA patients after initial takedown was 18% at year 10, while the cumulative risk of conversion to permanent ileostomy only was 8% at year 10. Conclusions: In this population-based cohort of UC patients, the cumulative risk of colectomy after UC diagnosis was 16% at year 10 and 28% after 30 years of disease. The cumulative risk of requiring a subsequent surgery after colectomy was greater than 50% after 10 years. These results highlight the need for early medical intervention in ulcerative colitis. [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] . Pts were identified with UC who had ALM lesions, and a subset with high-grade dysplastic polyps were defined as our study cohort. Pt demographics, disease characteristics, surveillance protocol, histopathology of biopsies and colectomy specimens were evaluated. Results: 113 pts were identified with dysplastic lesions.102 (90%) of these had UC, 5(4%) had Crohn's disease and 6(6%) had indeterminate colitis. 30 of the 102 (29%) pts with UC had ALMs in the absence of synchronous flat dysplasia; of which 9(30%) had HGD in these polyps. The mean age of cohort was 61 yrs (28-75 yrs); 6/9(66%) were male. The mean duration of disease was 16.3 yrs (6-26 yrs). 7/9 (77%) pts had pancolitis.9 pts had 10 ALMs with HGD. 9/10 (90%) of these polyps were within the area of colitis. The polyps were found in: 1(10%) in cecum, 3(30%) in ascending colon, 1(10%) in descending colon, 3(30%) in sigmoid colon, and 2(20%) in rectum. Most polyps (8/10) were adenomatous and 2/10 were villous. The mean polyp size was 5.4 mm (2-12mm). 32 surveillance colonoscopies were performed (mean 3.6 colonoscopies/pt). The pts were followed for a mean of 64.5 mos (40-87 mos). 3/9 pts (33%) had colectomy. No pts in this cohort were detected to have carcinoma in surveillance biopsies and/or in their resection specimens. Conclusions: Our data suggests that the presence of high grade dysplasia in ALMs does not mandate colectomy. Continued close observation is suggested in this pt cohort after complete excision of polyps.Further prospective evaluation of this pt population is merited. Purpose: Postoperative ileus is a distressing and frequent adverse event following laparoscopic cholecystectomy (LCE). Aims: The goal of this investigation was to evaluate the effects of the prokinetic drug itopride hydrochloride (ITOPRIDE) on gastric motility in the early postoperative period following LCE. Methods: Transcutaneous electrogastrography (EGG), a noninvasive diagnostic method allowing a monitoring of gastric myoelectric activity, was used to evaluate variations in gastric motility. 50 patients undergoing LCE were observed for 3 days beginning at the day of surgery. In a randomized, double blind manner, patients were administered ITOPRIDE (50 mg/day) or placebo (sacharose). EGG records were performed at 6, 24, and 48 hours post surgery in a fasting state and after stimulation with a liquid bolus. EGG data were recorded by a Microdigitrapper device and analyzed using spectral analysis and Fourier transformation. Results: When comparing both groups (ITOPRIDE and placebo), nausea was found significantly more frequently in the placebo group at the day of surgery as well as on postoperative days 1 and 2. The incidence of vomiting did not differ between groups. Differences in the EGG records were observed; on the day of surgery, 56% and 40% of the patients in the ITOPRIDE and the placebo group showed a physiological EGG curve, respectively. On the 1st postoperative day it was 68 and 56% and on the 2nd postoperative day 88% and 80%. However, these differences failed to reach a significance level of p < 0.05, most likely because of the relative small group sizes.
Conclusions:
The perioperative use of ITOPRIDE accelerates the normalization of the EGG curve after LCE. ITOPRIDE was well tolerated, and no serious adverse events were observed during therapy. Thus, these results suggest that ITOPRIDE can be a useful enhancer of postoperative ileus restoration following LCE. Purpose: In ulcerative proctitis (UP), the extent of the disease, not taken into account by the disease activity index (DAI), along with its severity is a significant characteristic of the disease. This study looked at the effect of 2 modes of treatment by mesalamine suppositories on disease extent. Methods: In a randomised clinical trial, patients with mild or moderate UP limited to 15 cm of the anal margin, evidenced by a Disease Activity Index (DAI) between 4 and 11, were randomized to mesalamine 500 mg sup BID (n = 44) (Canasa , Axcan Pharma) or 1 g HS (n = 39) for 6 weeks. The extent of UP from the anal margin was measured by endoscopy at baseline, and after three weeks, and six weeks of treatment. The effect of treatments on disease extent was compared after 6 weeks of treatment within each group by Student t-test for paired data and between groups by ANCOVA.
Results: There was a significant decrease (p < .001) in mean (sd) length of disease extent between baseline and after six weeks in both groups: from 12.4(5.4) cm to 3.5(7.8) cm for 500 mg BID and from 10.5 (4.2) cm to 1.5 (3.2) cm for 1 g HS. There was no significant difference between the groups at six weeks for disease extent when adjusting for baseline values. A significant reduction (p < .001) also occurred in scores of mucosal appearance from baseline to six weeks (greater than 70%) within both groups, with the greater decrease occurring within three weeks. Conclusions: Both mesalamine suppository treatments were effective in significantly reducing the length of disease extent after six weeks. This effect, along with the reduction of disease activity, is important for the overall patient well-being.
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Purpose:
The small bowel is the most commonly affected site of Crohn's disease. Localized disease with transmural inflammation can lead to strictures. Small bowel strictures are a diagnostic issue. Radiology offers some options but false negative examination can occur. M2A Capsule Endoscopy (Pillcam) seems to be a promising noninvasive diagnostic tool for the study of entire small bowel. Due to the risk of retention, the capsule is controindicated in patients with suspected bowel strictures. The M2 Patency Capsule (M2PC) consists of an ingestible, time-controlled, dissolvable capsule that is the same size as Pillcam. M2PC is composed of a dissolving lactulose body surrounding a Radio Frequency Identification tag, that can be relieved by a Radio Frequency scanner. Purpose of the study is to assess the ability and the safety of M2PC in detecting bowel strictures in patients (pts) with small bowel Crohn's disease and clinically suspected strictures. Methods: Ten pts,5 male and 5 female, mean age 45 yr (± 17,6), with clinical pattern of recurrent cramping abdominal pain and/or abdominal mass, received small bowel follow-through (BFT) and subsequently ingested M2PC. Patients were scanner tested 36-48 hours after ingestion. If M2PC was detected after this time, the presence of a stricture was suggested Results: BFT showed reduction of small bowel lumen only in 4/10 pts. Instead after M2PC ingestion in 8/10 pts could be supected an ileal stenosis: 4/10 patients experienced abdominal pain and nausea or vomiting probably due to the blockage of the patency capsule in the stenosis (the capsules dissolved after within a mean of 56 hours and the patients then clinically improved) and 4/10 pts were asintomatic, but the patency capsule was detected in abdomen after 48 hours. Only in 2/10 pts (one with reduction of
Results:
The racial distribution and disease characteristics of the study population are shown tables 1 and 2. Disease distribution in UC was proctitis 13%, left sided colitis 27% and pancolitis 56%. With CD, one patient had perianal involvement, 31% colonic disease and 67.5% ileocolonic disease. Strictures were seen in 36.6% of CD patients. Of the UC patients 86% needed 5ASA compounds for maintenance of disease remission, 33% required corticosteroids and 16% were on azathioprine.Only one patient required cyclosporine. In the CD group 88.3% were on 5ASA, 27.1% were on long term antibiotics, 44.1% required steroids, 42% were on maintenance azathioprine and 10.4% (all African American) required maintenance infliximab. Two patients were on adalimumab for ankylosing spondylitis and had not required any other medication for maintenance of remission in CD. One patient developed a colon cancer after 24 yrs of UC and 2 patients had dysplasia on surveillance biopsies after 8 and 14 yrs of UC respectively. 1-19) . The standard infusion group had a total of 27 infusion reactions (14 mild, 11 moderate, 2 severe). 49 patients received rapid infusions (22 M 27 F). There were a total of 253 rapid infusions with a mean number of infusions per person of 5 (range 1-13). 96% (47/49) patients were on immunomodulators. The rapid infusion group had a total of 13 infusion reactions (7 mild, 6 moderate). 9/49 (18%) patients in the rapid infusion group had to return to standard infusions due to infusion reactions. The rate of infusion reactions for standard infusions compared to rapid infusions is comparable: 5.6% vs. 5.1% (p = NS). However, when taking into account those who had received both standard and rapid infusions, the rapid infusions had a slightly higher rate of infusion reactions, but this was not significant (0.05 vs. 0.11, p = NS).
Conclusions:
A rapid 1-hour infusion of Infliximab is well tolerated by a select group of patients and is not associated with an increased rate of transfusion reactions.
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Characterization of Large Polyps in Ileal Pouch-Anal Anastomosis in Patients with Underlying Ulcerative Colitis Benjamin Schaus, D.O., Bo Shen, M.D. * Department of Gastroenterology, Cleveland Clinic, Cleveland, OH.
Purpose: Restorative proctocolectomy and ileal pouch-anal anastomosis (IPAA) are the procedures of choice for patients with ulcerative colitis (UC) who require surgery. Polyps may occur in a patient's pouch or rectal cuff. The etiology, malignant potential, and management of these polyps are not known. The aim was to characterize clinical features of large polyps in IPAA in patients with UC. Methods: We searched our 3000-case Pouch Database for UC/IPAA patients with large polyps of the pouch (size ≥ 1 cm). Patients with other underlying diseases of the colon requiring total proctocolectomy and IPAA were excluded.Clinical, endoscopic, and histologic data were analyzed. Results: Twenty patients (10 males and 10 females; mean age of 45.4 ± 14.6 yrs) with polyps in the IPAA were identified with a prevalence of 0.8%. The mean time interval from IPAA performed to pouch polyp diagnosed was 7.1 ± 3.8 years. Indications for proctocolectomy and IPAA were refractory UC (N = 16; 80%) or UC with dysplasia (N = 4; 20%). Of the 20 patients, 66% had polyps at the pouch and 34% had polyps at the rectal cuff; 85% had a single polyp and 15% had 2 or more polyps; 80% had pedunculated polyps; 95% had inflammatory polyps; 1 patient (5%) had a dysplastic/neoplastic polyp (adenocarcinoma) in the rectal cuff who had initially underwent proctocolectomy and IPAA for UC with dysplasia. The average size of these polyps was 1.93 ± 1.2 cm. 19 patients (95%) with polyps were symptomatic and the all polyps arose from a background of mucosal inflammation with chronic pouchitis, cuffitis, or Crohn's disease of the pouch. In addition to medical therapy (antibiotics, 5-ASA, steoids, or immunomodulators), endoscopic polypectomy was performed in 16 patients. The pre-and post-polypectomy Pouchitis Disease Activity Index symptom scores were 3.13 ± 1.77 and 1.13 ±1.24 (P = 0.043), respectively. 2 patients underwent pouch resections for dysplasia/neoplasia of the cuff and chronic refractory pouchitis, respectively. Conclusions: While the majority of large pouch polyps in UC and IPAA patients were benign and inflammatory types, this study found one neoplastic polyp in a rectal cuff. In patients, particularly, with pre-operative dysplasia, polyps at the rectal cuff can be dysplastic or neoplastic. The fact that all large pouch polyps arose from the background of chronic pouchitis, cuffitis, or Crohn's disease, would suggest possible etiology of inflammation.
Polypectomy combined with medical therapy may lead to improvement in symptoms. . We compared the frequency of severe infection, neoplasm, and mortality between the 2 groups. The exclusion criteria were 1) age < 20 at the time of entry; 2) enrollment in the ACCENT trials; and 3) infliximab infusion for diseases other than Crohn's disease. Severe infection was defined as an infection which occurred within 2 months of the last infliximab infusion requiring hospitalization and IV antibiotics, infection by opportunistic organisms or causing a near death experience. All neoplasms were included except basal cell carcinoma.
Results:
The 2 groups were comparable in age, gender, disease location, and mean number of IBD-related surgeries (2.1 ± 3.2 vs 1.7 ± 1.9). In the infliximab group, 322 patients received a total of 2168 infusions with a mean follow-up of 2 years after the start of infliximab therapy and a mean of 13.7 years since diagnosis. 26.7% of patients received infliximab prior to any other immunomodulators and 11.8% of patients received no concurrent immunomodulators. Of 217 patients in the immunomodulator group with a mean follow-up of 15.6 yrs since diangosis, 48.4% had 6MP/AZA, 5% had steroids, 4.1% had MTX, 42.5% received more than one immunomodulators.
Inflixmab N = 322 Immunomodulators N = 217
Severe Infections 17 (5.2%) 10 (4.6%) Neoplasm 7 (2.2%) 5 (2.3%) Mortality 8 (2.5%) 4 (1.8%)
Conclusions: There were no statistical differences in the frequency of severe infection, neoplasm, and mortality in Crohn's disease patients between the infliximab and immunomodulator groups. Mortality of the 2 groups was 2.5% and 1.8% respectively. Purpose: Evidence is mounting that bacteria play a role in the pathogenesis of IBD. Probiotics have shown efficacy in the treatment of ulcerative colitis (UC) although the mechanism of action is unknown. PPAR-γ is expressed in colonic epithelial cells and inhibits cytokine activation. In UC, PPAR-γ levels are low. The aim of this study was to determine whether probiotics (VSL#3) up-regulate PPAR-γ as their mechanism of action. Methods: Patients with active and inactive UC were screened for eligibility, consented and the disease activity index (DAI) calculated from a questionnaire and a sigmoidoscopy with biopsy. In this open labeled study, patients were treated with VSL#3 orally for 4 weeks. Concurrent use of mesalamine was permitted, but steroids, antibiotics or immunomodulators were prohibited. At the end of 4 weeks, a sigmoidoscopy with biopsy was repeated and the DAI calculated. Real time PCR was performed to assess the level of PPAR-γ from the biopsy samples pre and post VSL#3. Results: 15 patients were enrolled; 8 with active and 7 inactive disease. Baseline DAI was 5.6 ± 2.6 for patients with active disease and 0.7 ± 0.8 in the inactive group (p = 0.001). Following VSL#3 treatment, 75% of patients with active disease achieved remission (DAI ≤2) with the DAI decreasing by 66% from 5.6 ± 2.6 to 1.5 ± 1.8 (p = 0.01). This was due to statistically significant reductions in stool frequency, sigmoidoscopy scores and global assessment. DAI also decreased in those with inactive disease (p = ns). However, only the endoscopic subscore was significantly decreased at 4 weeks (p = 0.04). At baseline, PPAR-γ levels were similar between patients with active and inactive disease (p = 0.8). Following VSL#3, PPAR-γ RNA levels were reduced by 45% (p = 0.001) in active disease and by 45.6% (p = 0.1) in those with inactive disease. At 4 weeks, PPAR-γ levels were similar between patients with active disease that achieved remission and patients with inactive disease (p = 0.6).
Conclusions: 75% of patients with active disease achieved remission with VSL#3. This was associated with a significant reduction in PPAR-γ levels from baseline in patients with active disease. Overall there was no significant correlation (p = 0.25) between reduction in the DAI and reduction in PPAR-γ . This data indicates that the mechanism of action of probiotics is not through an upregulation in PPAR-γ but is perhaps the result of immune tolerance. Supported by NIH grant M01-RR0132. Purpose: The etiology of flare-up in IBD is unknown but is believed to be partially related to environmental factors. Sleep disruptions have been implicated in worsening of disease course in many inflammatory conditions such as rheumatoid arthritis, lupus erythematosus and asthma. Links between sleep and inflammation are also supported by studies. We questioned whether sleep disturbance could also be a trigger for inflammation in patients with IBD. The aims of our study were to determine (1) the prevalence of sleep disturbance in patients with inactive IBD and (2) Purpose: Broad-spectrum antibiotics are often used in patients with Inflammatory Bowel Disease (IBD) despite the lack of well-designed, placebocontrolled trials. Rifaximin is a new synthetic antibiotic that has a broad spectrum of activity and few side effects due to minimal absorption from the gastrointestinal tract. Unlike ciprofloxacin and metronidazole, rifaximin has similar coverage with no systemic side effects. In order to determine the role of rifaximin in the managment of patients with IBD, the following study was undertaken. Methods: 27 patients with IBD, 11 with Crohn's disease and 16 with Ulcerative colitis were included in the study. There were 16 female, 11 male patients, mean age 33 ± 8. All patients presented with mild to moderate disease manifested as diarrhea and/or abdominal pain. All patients were currently being treated with mesalamine at high dosage (mean 4.4 ± 0.8 grams). Patients were excluded if they had taken other medications, such as infliximab, 6-mercaptopurine or azathioprine. Due to persistent (n = 9) or recurrent disease (n = 18), the patients were given either (Group 1) prednisone 40-60 mg orally daily or (Group 2) rifaximin 400 mg orally twice daily. If the patients improved, the prednisone was continued for 2 weeks and then tapered, the rifaximin was continued for 2 months and then tapered. Response was defined as induction of remission without the addition of other medications. At the judgement of the clinician caring for the individual patient, additional therapy was provided. Results: Of the 27 patients included in the study, 14 patients were given prednisone, 13 patients were given rifaximin. All but one patient in the prednisone group responded to therapy. The one patient who did not respond had Crohn's disease and was subsequently given infliximab resulting in a complete response. Thirteen patients were given rifaximin. Of these patients, all but two responded; both required the addition of corticosteroids, one was hospitalized.
Conclusions: This study demonstrates that the broad spectrum antibiotic rifaximin may be effective in patients with IBD who require further treatment with corticosteroids. However, the steroid sparing efficacy must be considered in a well-defined subset of patients. The use of rifaximin in ulcerative colitis and Crohn's disease requires further evaluation in larger studies. Purpose: The pathogenesis of mucosal injury in IBD involves enhanced production of reactive oxygen species. The aims of this study were to examine the effects the antioxidant N-acetylcysteine (NAC) alone and in combination with mesalamine (5-ASA) on mucosal healing and repair in dextran sulfate sodium (DSS) induce colitis. Methods: Colitis was induced by oral administration of 4% DSS in the drinking water for 4 days. SD rats (250-275g) were randomized to five groups. Group 1 control, Group 2-5 received DSS in drinking water and Group 3-5 were further randomized to also receive daily intracolonic treatment with: 5-ASA (100 mg/kg) plus NAC (40mM), (Goup3); 5-ASA (Group 4); and NAC (Group 5) for four days. Microscopic indices of colonic injury were scored and tabulated. Histological features examined included epithelial damage and mucosal ulceration. Additional measures included serum CRP and cytokine gene expression in colonic tissues by ribonuclease protection assay (RPA). Results: DSS treatment produced mild to moderate colitis. The aggregate microscopic injury score for DSS treated animals was 5.5 ± 2.0; maximal score 15. Monotherapy with 5-ASA and NAC caused reduction in aggregate scores (4.1 ± 0.9 and 4.0 ± 1.1, respectively) that were not significantly different from DSS alone, P > 0.1. In contrast, combination therapy with 5-ASA plus NAC reduced global injury by 67% to 1.82 ± 0.8. Furthermore, 5-ASA plus NAC caused significant improvement in epithelial damage when compared to DSS alone: 0.3 ± 0.2 vs 1.5 ± 0.3, P < 0.02. DSS colitis was associated with elevated CRP values; 7.0 ± 0.6 µg/ml. CRP levels were reduced substantially by concurrent treatment with 5-ASA plus NAC (1.0 ± 0.3 µg/ml (1994-present) , patients with a clinical diagnosis of UC were selected. Those with less than pancolitis and in whom a "cecal red patch" or "periappendiceal red patch" was described were identified. Clinical and histologic characteristics of these patients were then reviewed using electronic medical records. Results: 688 UC patients who had complete colonoscopy were identified, 367 of whom did not have pancolitis (51% male). 29 (7.9%) of these patients had endoscopically described PARP (17% proctitis, 6% proctosig, 56% leftsided, 19% extensive, 1% unknown), 20 of whom were further confirmed by biopsy of the area. None of the 29 patients had a prior appendectomy, 8 (28%) were ex-smokers, and 26 (79%) were male. In 16 of 24 (67%) exams in which biopsies were obtained, the histologic activity in the PARP paralleled the activity documented in the distal colon. 2 patients required colectomy for fulminant colitis at the time of referral. Of the remaining 27 patients, 23 had median 7 y f/u (range 1-16y), and these referred patients had a total duration of disease of 12 y (median, range 1-22 y). 18/23 patients had colonoscopies during their f/u which identified progression to greater extent of disease in 5 (28%) at 13 y (median, range 9-21 y). One progressing patient developed dysplasia during f/u after 18 years of disease and underwent colectomy. Conclusions: In our tertiary care center, we have also observed the association of peri-appendiceal inflammation in a subset of patients with the otherwise clinical features of UC. The lack of appendectomy, male preponderance, and parallel activity to the distal colon are important observations that warrant further investigation into the potential relationship of peri-appendiceal red patch and UC.
Purpose: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract with a poorly understood pathogenesis. Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) potently regulates the immune system through the activation of PAC1 (Trends Mol Med, 2003, p. 211-7) , however, the role of PACAP and its receptor, PAC1, in inflammatory colitis is unclear. The purpose of this study is to elucidate the role of PACAP and its receptor, PAC1, in an experimental mouse model of colitis. Methods: Colitis was induced in 8 adult PAC1 +/+ and 7 PAC1 −/− mice with 2.5% DSS given orally for 6 days. Measurements of water and food intake, body weight, observations of mice activity and stool appearance were made at baseline and daily thereafter for six consecutive days. On the 7th day the intact colon from both groups of mice were dissected and examined macroscopically and microscopically to determine the degree of ulceration that was scored in a blinded fashion. Results: PAC1 −/− and PAC1 +/+ mice, both showed significant body weight loss following treatment with DSS. PAC1-/-mice showed a slightly lower, but statistically insignificant, intake of food (7.7 ± 5.47 g/day vs 9.5 ± 7.31 g/day) and water (11.89 ± 13.4 g/day vs 16.0 ± 14.70 g/day), compared to the PAC1 +/+ group. Using a macroscopic score scale with a maximum of 8 and a minimum of 0, the PAC1-/-mice had a higher macroscopic score (3 ± 0 vs 0 ± 0, p < 0.05, n = 15), compared to the wild type. A score of 0 indicates a normal colon, whereas a 3 indicates a colon with inflammation, ulcer ( < 2cm), and colonic wall thickening. The colonic length to weight ratio was lower (29.07 ± 10.02 vs 14.86 ± 2.60, p = 0.013) in the PAC1 −/− mice, indicating a higher level of inflammation compared to the wild type group. The H and E stained slides of the distal and proximal confirmed that in the PAC1-/-group, a dense mucosal infiltrate, containing neutrophils, lymphocytes and macrophages, was significantly more abundant than in the PAC1 +/+ group. Conclusions: PAC1 receptor deficient mice exhibited significantly higher levels of colonic inflammation. These data suggests that the PAC1 receptor plays a protective role against colonic inflammation in mice, and may have the potential to help design future studies for treatment, and or, prevention of IBD. Purpose: Patients with inflammatory bowel disease are highly susceptible to develop osteoporosis or osteopenia, a condition that is more commonly occurred in patients with corticosteroid use. The aim of the present study was to determine the prevalenceof low BMD in corticosteroid ever-users and related risk factors among Iranian IBD patients. Methods: Totally, 94 corticosteroid ever-user IBD patients with a mean duration of 11.7 ± 17.7 months corticosteroid use, were included. Bone mineral density was measured at lumbar spine (L1-L4), femoral neck, and radius 33% by dual energy x-ray absorptiometry (DXA). Initial data were gathered by a questionnaire and blood samples were obtained to measure biochemical markers. Student t test, chi square, ANOVA, and Tukey HSD were applied, when appropriate. To find predictive variables for BMD, step wise regression analysis was performed.
The study population included 34 males and 60 females with the mean age of 38.4 ± 13.2 years. Of 94 patients, 67 had ulcerative colitis (UC) and 27 had Crohn's disease (CD). Seven patients (7.4%) had osteoporosis and 35 (37.2%) were osteopenic. Osteoporosis and osteopenia were most pronounced at lumbar spine both in UC and CD patients. Lumbar spine t score was inversely correlated with age and 25-OH vitamin D level (r = −0.37, p < 0.0001, r = −0.29, p < 0.007, respectively). Femoral neck t score was inversely correlated with age (r = −0.27, p < 0.01). Low BMD was associated with higher prevalence of pathologic fracture (p < 0.04). Osteoporotic patients had lower level of vitamin D and older age when compared with both osteopenic and normal subjects (p < 0.05 for all differences).
Step wise regression analysis revealed that lumbar spine T-score could be predicted by age (p < 0.0001), whereas femoral neck T-score was predicted by age (p < 0.0001), BMI (p < 0.01) and history of smoking (p < 0.02). Radius 33% t-score was predicted by age (p < 0.0001) and BMI (p < 0.01).
Conclusions:
Corticosteroid use is associated with lower BMD and higher prevalence pathologic fracture among Iranian patients with IBD. Patients' age is the most important factor correlating with lumbar spine and femoral neck density. Meanwhile, lumbar spine T-score could be predicted by age and femoral neck by age, BMI and history of smoking. Purpose: Efficient conversion of the thiopurine drugs 6-mercaptopurine (6-MP) or its pro-drug azathioprine (AZA) to the active 6-thioguanine nucleotide (6TGN) metabolites is decisive to clinical efficacy. The principal catabolic metabolite, 6-methylmercaptopurine (6MMP), is formed via the competing thiopurine methyltransferase (TPMT) pathway. We first established the clinical utility of measurement of these intracellular metabolites in IBD in order to optimize outcomes. The aim of this study was to assess the clinical utility of 6-MMP to 6-TGN ratios in predicting efficacy & toxicity to thiopurine therapy. Methods: 6-MP metabolite levels were measured prospectively at 3-6 monthly intervals, or at the time of a clinical relapse or adverse events, in pediatric patients with Crohn's disease on 6-MP or AZA (>3 months). Therapeutic response was determined by Harvey Bradshaw index and physical exam ascertained at each visit corresponding to a 6-MP metabolite measurement (clinical evaluation point). Erythrocyte 6-TGN and 6-MMP concentrations (pmol/8 × 10 8 RBC) were measured (HPLC) at Ste Justine Hospital. Logistic regression analysis was carried out to evaluate associations between metabolites and clinical response. Results: Results were analyzed as continuous variables for 1787 clinical evaluation points in 267 patients and data were classified into quartiles. One or more relapses were observed in 53.7% of cases. Non-compliance was observed in 6.25% of patients. 6-MMP values greater than 5119 and less than 851 were associated with increased likelihood of relapse (Odds Ratio [OR] 1.41, 95% CI 1.1-1.9, and OR 1.38, 95% CI 1.1 -1.8 respectively, p = 0.02). A significantly higher risk for relapse was associated with high (>24.3) ratios of 6MMP/6TGN (OR 1.33, 95% CI 1.1-1.8 p = 0.04). Ratios < 4.2 correlated with TPMT deficiency. Clinical remission did not correlate with dose of 6-MP/AZA. Hepatotoxicity (25.8% of subjects) was associated with increased 6-MMP levels (OR 6.2, CI 3.2-12.3, p < 0.05) and high 6-MMP/6-TGN ratios (OR 7.2, 95% CI 3.8-13.8, p < 0.05). Conclusions: Excessive TPMT metabolism, reflected metabolically by high 6-MMP/6-TGN ratios, is associated with lower probability of clinical response and increased likelihood of hepatotoxicity. The determination of 6MMP/6TGN ratios provide the clinician with useful tools for optimizing therapeutic response to thiopurine drugs in IBD Purpose: Gastroduodenal Crohn's Disease (GDC) is an unusual condition manifesting with nausea, emesis, and abdominal pain. GDC can be complicated by duodenal strictures, gastric outlet obstruction, and rarely pancreatitis. We report a rare case of GDC with ampullary reflux of barium contrast into the biliary system. The patient is a 38 year old man with GDC diagnosed by endoscopy, laparotomy and radiographs 12 years prior to admission. Treatment was initiated with steroids for one year followed by long-term acid suppression and promotility agents. Extra-Intestinal manifestations included Erythema Nodosum (EN), bilateral knee effusions, and arthritis. The patient presented with nausea, vomiting, non-bloody diarrhea, and abdominal pain and two days of left knee pain and tender lumps on bilateral lower extremities. Medications included 6-MP 25mg/d, famotidine, and metaclopromide. Exam revealed mild tenderness at McBurney's point and EN below the knees. Patient had a white cell count of 15.1, albumin 2.0 and normal Hematocrit, amylase, and liver enzymes. The patient was diagnosed with a Crohn's flare and treated with intravenous steroids. Small Bowel radiographs and endoscopy revealed innumerable gastric pseudopolyps, anatomical pyloroduodenal distortion, free-flowing bile from a deformed ampulla, ready reflux of contrast into the common bile duct and pancreatic duct (PD), and a tight mid-duodenal stricture; single-contrast barium enema revealed newly seen terminal ileal string sign. Ampullary and gastroduodenal biopsies revealed chronic inflammation. The patient was discharged on TPN, oral prednisone, 6-MP 50mg/d, acid suppression and promotility agents. Outpatient ERCP revealed a flat wide-open ampulla, normal common bile duct, and a mildly dilated PD. Sphincter of Oddi manometry revealed pressures less than 30mm Hg. Colonoscopy with biopsies revealed mild chronic ileitis and pan-colitis. We describe a case of initial GDC causing ampullary destruction with biliary reflux. This patient subsequently developed ileocolitis. Isolated GDC without ileal involvement is extremely rare. There are few case reports describing pancreatitis secondary to Crohn's disease; ampullary incompetence is postulated to be the etiology. Ampullary reflux into the PD with Crohns has only previously been documented once in literature. Although our patient did not have pancreatitis, it is important to recognize that GDC can have ampullary complications.
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Results: More IFX 5-(61.2%) and 10 mg/kg (60.3%) pts had mucosal healing at wk 8 vs PBO (32.4%, both p < 0.001). At wk 30, 48.3% and 52.9% of IFX 5-and 10 mg/kg pts, respectively, had mucosal healing vs 27.5% of PBO (both p < 0.001). At endoscopy at wk 8, more pts receiving IFX 5-(25.2%) and 10 mg/kg (24.4%) had no evidence of active colitis (endoscopic score of 0) vs PBO (8.2%, p < 0.001). At wk 30, 27.7% and 30.6% of IFX 5-and 10 mg/kg treated pts, respectively, were free of evidence of active colitis vs. 9.4% of PBO (both p < 0.001). Proportion of pts in clinical remission was similar for the IFX at wks 8 and 30 (range, 29.8% to 36.4% vs 10.2% to 13.1%; PBO; p < 0.001 all comparisons). Proportion of IFX-treated pts in clinical remission at wk 30 was 4 fold greater for pts with mucosal healing at wk 8 (48.3%) vs pts without mucosal healing at wk 8 (9.5%). Conclusions: IFX is effective in inducing mucosal healing and remission in UC pts. Clinical remission at wk 30 occurred 4 times as often for pts with mucosal healing at wk 8. Purpose: Crohn's disease is associated with impaired HRQOL. This analysis investigated HRQOL outcomes during maintenance therapy with natalizumab (a humanized monoclonal IgG 4 antibody to α4 integrin) in the ENACT-2 trial where higher rates of sustained response and remission were observed compared with placebo.
Methods:
Patients who responded to natalizumab induction therapy (n = 339) were randomized to natalizumab 300 mg (n = 168) or placebo infusions (n = 171) given monthly for up to 12 months. HRQOL was measured by the Inflammatory Bowel Disease Questionnaire (IBDQ) and the Short Form-36 (SF-36) at months 0, 3, 6, 9, and 12. Higher scores indicate better HRQOL. A minimally important difference (MID) is defined as 16 pts for Total IBDQ and 5 pts for SF-36 summary scores.
Results:
The change for all IBDQ scales from ENACT-1 baseline was significantly greater (p < 0.05) in natalizumab-treated patients at all timepoints. Changes in 7 of 10 SF-36 scales were significant by month 3 and all were significant in months 9 and 12. A significantly greater proportion of natalizumab patients achieved MID on the Total IBDQ at months 6-12 and the SF-36 PCS at months 3-12. Mean scores for physical function, social function, role-emotional, and mental health approximated US norms at month 12.
Change 
Conclusions:
In this small exploratory cohort, remission was maintained in pts with CD treated with ADA 40 mg/wk or 40 mg eow for 1 year. ADA was safe and well-tolerated in this study. A larger study, powered to definitively assess the long-term efficacy of ADA, is ongoing. We describe a 40 year old Caucasian male with a 7 year history of fistulizing CD who had initially responded to infliximab infusion. Unable to achieve therapeutic levels of 6TG on 6MP, the patient was switched and maintained on 6TG. The progression of his disease resulted in severe inflammation of the rectosigmoid area, spiking fevers, and frequent hospitalizations. The patient then underwent autologous stem cell transplant at an outside facility. The patient's disease remained quiescent for 2 years and then flared with fever, abdominal pain, distention and diarrhea. After treatment with infliximab and IV steroids, the patient continued to have fever and severe diarrhea with hematochezia. After high dose IV steroids were started at an outside center, subcutaneous methotrexate was tried but discontinued due to neutropenia. Total parenteral nutrition was started for significant weight loss and progressive hypoalbuminemia. He was admitted to our hospital with new onset productive cough, fevers, worsening abdominal pain and diarrhea. Sigmoidoscopy revealed severe friable, ulcerated and intensely inflamed mucosa. Abdominal films showed persistent ileus of the small bowel and colon. Aspergillus infection was also diagnosed by CT guided biopsy of new pulmonary nodules. The patient refused surgery despite medical and surgical advice. Tacrolimus therapy was initiated with IV dosing at 0.03mg/kg/day as continuous infusion and titrated to oral dosing with a goal level of 10-15 ng/ml. Within 2 weeks of starting tacrolimus, the patient responded with firmer nonbloody stools, weight gain, and an increase in serum albumin. One month after therapy began, the inflammation and ulceration had improved on sigmoidoscopy. His pulmonary symptoms cleared with concurrent treatment with voriconazole. Conclusions: Based on our short term anecdotal experience, tacrolimus is a therapeutic option in this patient with severe recurrent CD refractory to steroids, infliximab, and stem cell transplant who was intolerant to methotrexate. Lisbeth Selby, M.D., Houssam Mardini, M.D., M.P.H., Willem J.S. de Villiers, M.D., Ph.D. * Digestive Diseases and Nutrition, University of Kenctucky, Lexington, KY. Purpose: Patients (pts) with chronic diseases often do not receive preventive health services at the same rate as the general population. The issue has not been fully explored; hypotheses include such issues as consumption of physician time by the complexity of a chronic condition and the idea that primary physicians, who usually provide such services, are intimidated by the complexity of the chronic disease, remaining only superficially involved in the care, if at all. We performed a cross-sectional survey of our IBD clinic pts to assess the rates at which they receive 10 US Preventive Services Task Force (USPSTF) recommended services (ones rated either A or B). Methods: One of several IBD specialists surveyed 49 consecutive adult IBD pts at a single routine clinic visit. We combined chart data and patient report to determine receipt of services. We also gathered data on demographics, insurance coverage, disease duration, and IBD type. Hanauer, M.D., Richard Bloomfeld, M.D. G.E., Mayo Clinic, Rochester, MN; GE, Massachusetts General Hospital, Boston, MA; GE, Univ of Chicago, Chicago, IL and GE, Wake Forest University, Winston-Salem, NC. Purpose: The FDA indicated dosages of Asacol (mesalamine) delayedrelease tablets are 2.4 g/day for the treatment of mild-moderately active ulcerative colitis (UC) and 1.6 g/day for maintenance of remission. There is anecdotal evidence that maintaining the induction dose may be better than dose-reduction to prevent relapse. This study used a naturalistic, retrospective design to compare the outcomes of UC patients maintained on the dose used to induce remission with those whose maintenance dose was reduced.
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Provision of Preventive Health Services to IBD Patients
Methods:
The medical records from 411 UC patients from 39 geographically dispersed, community gastroenterology practices who had a disease flare between 1999 and 2003 successfully treated with Asacol without requiring steroids were reviewed. The review included the single flare of interest and the subsequent maintenance period. Outcome measures examined were maintenance of remission at 6 and 12 months post-induction, and% rated "normal" on the physician global assessment of symptom severity (PGA) at final data capture. The primary explanatory variable was the relation between maintenance (M) and induction (I) dose, coded as M = I vs. Sandborn, M.D., G. R. Lichtenstein, M.D., J. F. Colombel, M.D., S. Yan, M.S., B. E. Sands, M.D., D. Eisenberg, M.S., A. Olson, M.D., P. J. Rutgeerts, M.D. * Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN; Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA; CHU de Lille, Hospital Claude Huriez, Lille, France; Outcomes Research, Centocor, Inc, Malvern, PA; Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA; Clinical Research & Development, Centocor, Inc., Malvern, PA and Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium. Purpose: The effect of infliximab (IFX) on hospitalizations in UC was assessed in 2 randomized, controlled trials. Methods: 728 pts were enrolled in ACT 1 and 2. Pts were randomized (1:1:1) to placebo (PBO), IFX 5-, or 10 mg/kg. Treatment was administered at baseline, wks 2, 6, and then q8 wks. Number of UC-related hospitalizations was compared between groups, pooling data from both trials, using analysis of variance on van der Waerden scores. Similar comparisons were made between non-responders, responders not in remission, and pts in remission at wk 30, disregarding treatment group. Purpose: Patients with inflammatory bowel disease (IBD) are at risk for glucocorticoid induced osteoporosis. However, there is very limited data on the magnitude of this risk, and the duration and dose of steroids required to produce bone loss. The objective of this study is to prospectively determine the rate and degree of bone loss in IBD patients treated with corticosteroids. Methods: IBD patients who are being started on oral prednisone undergo baseline DEXA to determine bone mineral density (BMD) scanning and lateral vertebral assessment for fracture, baseline labs, and 1,25 (OH) Vitamin D levels. NTX levels are drawn after 1 month of prednisone therapy, and follow up DEXA scans are repeated at 3, 6 and 12 months after the initiation of prednisone. IBD patients, matched for disease activity, but not being started on prednisone will be studied as controls. Patients on prednisone undergo a standard steroid taper based upon clinical response. All patients are treated empirically with calcium 1500 mg/d and vitamin D 600 u/d. 38 patients will be entered in the steroid and control groups each. Baseline disease activity is scored using the Mayo Score for UC, and the Harvey Bradshaw Index for CD.
Results: To date, 16 patients starting on steroids have entered the study; 12 UC, 4 CD; mean age = 32.1, 10 male and 6 female, mean BMI = 22.2. All women were premenopausal. No patient had a history of fracture. Mean baseline t score of bilateral hips = −0.7. Mean baseline t score of L2−L4 = −0.6. 20% of patients were found to have baseline osteopenia in the hips, and 7% of patients had baseline osteoporosis in the hips. 14% of patients had baseline osteopenia at L2−L4, and 14% had baseline osteoporosis at L2−L4. 50% of patients had low baseline levels of 1, 25 (OH) vitamin D and were supplemented with ergocalciferol 50,000 units TIW. Mean NTX at 1 month = 14.7; no patient had an elevated NTX. At 3 months there was a mean decrease of 1.7% (range 0% -−6%) at the hips, and a mean decrease of 2.7% (range 1% -−6%) at L2−L4. No fractures developed as assessed by lumbar vertebral assessment.
Conclusions:
In this interim analysis, significant bone loss as defined by a greater than 5% decline in BMD can be seen as early as 3 months in these patients with active IBD being treated with a tapering course of prednisone, despite concurrent supplemental calcium and vitamin D. Continued prospective follow up at 6 and 12 months is underway.
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differ among groups at baseline (BL to identify all patients with a diagnosis of PSC. PSC patients were identified using regional databases (ERCP, health records, diagnostic imaging, transplant and histopathology) and were confirmed by chart review. Histopathology from colonoscopy records was reviewed in CHR patients with PSC and UC or CD for: 1) the number of biopsies taken during screening colonoscopy, 2) frequency of colonoscopies conducted between 2000 and 2005, and 3) the presence of CRC, dysplasia or a dysplasia associated lesion or mass (DALM). Results: During the study period there were 105 patients with PSC identified, 44 resided in the CHR and had UC or CD. Of the 44 patients who were eligible for screening, 5 (11.4%) were diagnosed with dysplasia (n = 2), DALM (n = 2) or CRC (n = 1) in the 5 year screening period. Two of these patients were diagnosed by screening colonoscopies, while the other three were not being screened regularly and were identified because of the development of symptoms. Of an expected 130 screening colonoscopies for dysplasia, only 56 (43%) were actually conducted and only 32% of patients had more than three quarters of their recommended colonoscopies attempted. Purpose: The lifetime prevalence of colorectal cancer in a patients with inflammatory bowel disease (IBD), ulcerative colitis or Crohn's colitis, is 3 to 6%. Endoscopic surveillance for dysplasia in patients with long-standing colitis is an accepted method of preventing death from colorectal cancer. Recent studies have suggested that the incidence of colorectal cancer in patients with long-standing colitis is decreasing. It is not clear whether the decrease in colorectal cancer is associated with a decrease in the incidence of dysplasia, to changes in the natural history of the disease or increased use of maintance therapy with mesalamine and/or immunosuppressive agents. Methods: In order to determine the role of mesalamine in the prevention of colon cancer, we evaluated mesalamine use in patients with long-standing ulcerative colitis and Crohn's colitis who had a duration of disease greater than 8 years. Demographic information, duration of disease, number of flares, hospitalizations, extent of disease, and other medications taken were recorded. The mean dosage of mesalamine was calculated using the total dose per time period studied divided by the number of days from the time of diagnosis to May 1, 2005. Results: One hundred-two patients were included in the study. There were 53 female, 49 male patients, mean age 64 ± 18 years. The mean duration of disease was 16.5 ± 8.8 years. All patients had received mesalamine for a mean period of 14.4 ± 7.1 years. The mean dosage of mesalamine in all patients was 2.6 ± 1.2 grams. None of the patients studied developed colon cancer. Four patients developed dysplasia (3.9%). The mean dosage of mesalamine in patients who had not developed dysplasia 2.6 ± 1.2 grams was significantly higher than patients who had developed dysplasia 0.8 ± 0.35 grams (p = 0.003). There were no significant differences between the groups regarding age, gender, duration of disease, extent of disease, or other medications, including 6-mercaptopurine/azathioprine. Conclusions: We conclude that the incidence of dysplasia and colon cancer in patients with IBD is decreasing. In patients with long-standing IBD, increased total mesalamine exposure appears to decrease the incidence of dysplasia. These results suggest that the decreased incidence of colon cancer in patients with IBD may be related to increased use of mesalamine for maintainance therapy. Purpose: Anecdotally, colonoscopy preparation seems to increase ulcerative colitis (UC) symptoms in some patients. The goal of this study is to determine if there is an association between colonoscopy preparation and disease relapse and to identify demographic factors, disease characteristics, or medications that are associated with increased symptoms after colonoscopy preparation. Methods: Initial assumption of a 20% flare rate led to a planned study size of 30. Thirty-five outpatients with a history of UC, intact colon and quiescent disease as determined by the patient were enrolled in a prospective ABA crossover study in which the patients served as their own controls (A = no prep B = colonoscopy prep). Patients were clinically evaluated with the Simple Clinical Colitis Activity Index (SCCAI) for the week prior to colonoscopy(A), week 1(B) and week 4(A) after colonoscopy. Data analysis used a mixed model to accommodate non-independence of repeated measurements.
Results: 31 patients completed the study. Mean age was 48 yrs, with 97% Caucasian and 55% men. Patients had UC for an average of 14.1 yrs (1.5-54 yrs), with an average of 0.64 hospitalizations/5yrs, 3.7 flares/yr, and 1.7 episodes requiring steroids/5yrs. 68% used 5-ASA, 36% used thiopurines, and 23% used chronic prednisone. 77% used fleets phospho-soda prep. Precolonoscopy, 2(6%) patients felt that preps lead to UC flares, while 3(10%) were unsure, and the majority (84%) thought there was no effect. Six (19%) pts required an escalation of their 5-ASA meds post-colonoscopy, 2 of these 6 pts flared as defined by a score ≥5 on the SCCAI at 1 wk post colonoscopy and 4 of 6 patients had a 1-3 point increase in their SCCAI. None required treatment with steroids or hospitalization. Multivariate modeling demonstrated that baseline SCCAI was predictive of increased SCCAI (p value < .001). Thiopurines were protective against increased symptoms (p = .01) and baseline prednisone use predicted increased post-colonoscopy symptoms (p = .02). There was a trend toward significance (p = 0.10) for the association between colonoscopy preparation and increased disease activity by SCCAI. Conclusions: Nineteen percent of patients required an increase in their 5-ASA meds post-colonoscopy. Baseline SCCAI and use of prednisone were predictive of disease flare, while thiopurines were protective. There was a trend toward significance in an association between colonoscopy prep and an increase in the SCCAI, additional subjects are being enrolled. LGD preceded different types of neoplasia in patients with UC and Crohn's colitis (CC). Methods: A retrospective chart review was conducted on 23 UC and CC patients with high grade dysplasia (HGD) and colorectal cancer (CRC) to seek those with LGD on surveillance colonoscopy. Only patients with flat dysplasia were included. Patients were grouped into HGD, Adenocarcinoma (ACA) without mucinous features, and ACA with mucinous/signet ring cell features. Clinical and disease characteristics of patients in the groups were compared. The Chi-square test was used for dichotomous variables and Analysis of Variance was used to compare groups on continuous variables. Results: There were no differences in demographics and disease characteristics (Table1.) Overall, 48% of neoplasia was preceded by LGD. HGD was preceded by LGD in 83% of patients (5/6). ACA w/o mucinous features was preceded by LGD 50% of the time (6/12). Cases of ACA w/mucinous features were not found to have antecedent LGD (0/5) ( Table 2) . Theses results were statistically significant (p = .022). All cases with ACA with mucinous features had CC. Conclusions: These preliminary results suggest that HGD is usually preceded by LGD. However, there may not be a definitive progression of LGD Purpose: Crohn's disease is associated with a loss of tolerance to commensal gut flora. In preliminary set of studies on germ-free mice, we observed a 3-4-fold induction in granulocyte-macrophage colony stimulating factor (GM-CSF) expression.These results suggested a potential role of GM-CSF in the mucosal response to commensal flora. To establish a mechanistic understanding of GM-CSF action in the treatment of Crohn's disease, we examined its effects in experimental model of DSS-colitis. Methods: Recombinant murine GM-CSF was pegylated (PEG-rmGM-CSF) to increase the half-life and to prevent rapid clearance from circulation. To determine the protective role of GM-CSF, mice were induced colitis by dministrating 5% DSS in the drinking water for 7 days and subsequently treated with or without PEG-rmGM-CSF. A group of mice was also treated with 440c to probe the involvement of the pDC in the respone to GM-CSF. Results were interpreted on the basis of histopathological evaluation, disease activity score as well as cytokine expression by real time RT-PCR and proteinarrays.
Results: Treatment of PEG-rmGM-CSF significantly reduced DSS-colitis associated weight loss, reduction in colonic size, bleeding score. However, the administration of mAb 440c along with PEG-rmGM-CSF led to a complete reversal of protective effect. Histopathological observation further demonstrated a profound reduction in inflammatory cell infiltrates. Real time RT-PCR analyses exhibited a significant increase in pro-inflammatory cytokine expression associated with DSS-colitis, however PEG-rmGM-CSF treatment led to a significant decrease in TNF alpha,IL-1beta expression and its complete reversal was observed following mAb 440 c treatment. The data were further confirmed by protein-array analysis. Administration of CpG DNA (a TLR 9 ligand) in colitis model exhibited protective effect through production of Type I Interferon. We also demonstrated that administration of PEG-rmGM-CSF further amplified CpG DNA induced Type I Interferons, IL-10 and IDO production Conclusions: These data suggest that GM-CSF protection in DSS-induced colitis may occur through interferon producing plasmacytoid DCs. These results also suggest that GM-CSF may be critical in regulating the mucosal immune response and contributing to a tolerogenic environment. Purpose: To study the immune-status of patients with fulminant ulcerative colitis (UC) who have been hospitalized for treatment with intravenous glucocorticoids. To study the long-term clinical outcome of this patient population. Methods: A cohort of oral steroid resistant UC patients (N = 201) were evaluated for Epstein Barr Virus (EBV) and cytomegalovirus (CMV) viral load and lymphocyte subsets during and subsequent to receiving IV steroids. EBV viral load data were also obtained for a cohort of patients (N = 64) with mild to moderate UC. Retrospectively, the clinical outcome data from the Kaiser Permanente IBD Registry were analyzed for a third cohort of patients (N = 663) who had received intravenous steroids during their initial hospitalization for fulminant UC. Results: Of the first cohort evaluated, 40% had measurable copies of EBV genome in their blood as compared to 0% of less severe UC patients, and 31% had CD4 counts below 200/mcL. Furthermore, 9% had both low CD4 counts and detectable EBV. Of a subset of patients screened for CMV (N = 73), only 5% were positive for CMV genome. Of the 663 patients reviewed from the Kaiser Permanente IBD Registry, 133 underwent colectomy during the index hospitalization. 497 patients left the hospital without colectomy, 82% of which tapered off steroids within 6 months of discharge, while 18% did not. However, 41% had re-started steroids by the first anniversary of their discharge date, 21% were re-hospitalized, and 10% underwent colectomy within 12 months of the initial discharge date. Conclusions: UC Patients receiving IV steroids experience significant immunosuppression, as evidenced by increases in EBV viral load and decreased CD4 counts. This contrasts with the EBV status and CD4 counts 5 of patients with mild to moderate UC, both of which are within normal range. UC patients from a community-based practice who were hospitalized for severe UC and treated with IV steroids were at significant risk for immediate colectomy before release (20%), while those who were released without colectomy were at significant risk for relapse of disease (72%) and for colectomy (10%) in the ensuing 12 months. Results: Fourteen patients with IBD and CMV colitis or pouchitis were identified, ten with ulcerative colitis (UC) (71%), three with Crohn's disease (CD) (21%), and one with indeterminate colitis (7%). Thirteen patients had a previously established diagnosis of IBD, while one was diagnosed with CMV and IBD concurrently. Present medications included steroids in 86% and immunosuppressives in 37% (only 14% were on neither). In 12 patients, CMV was identified after failure of conventional medical therapy. In two cases, CMV was not suspected preoperatively and was diagnosed by review of the surgical specimen. CMV diagnosis was based on characteristic histologic findings in 13 cases, and on colitic symptoms plus serologies and viral culture of blood in one case. CMV serologies were performed in 7 cases; IgG was positive in 5 (71%) and IgM was positive in 3 (43%). In 2 cases, both IgG and IgM were negative despite positive biopsy findings. In 11, CMV treatment consisted of intravenous ganciclovir and withdrawal of immunosuppressives; in 9 patients (82%), remission of disease was achieved and colectomy avoided. In the 2 other patients with a pre-operative diagnosis of CMV, surgery was the primary treatment due to severity of disease. Two patients presented with CMV pouchitis; one improved with therapy (ganciclovir and withdrawal of immunosuppressives), while the other did not. Conclusions: CMV colitis or pouchitis may complicate the course of IBD. CMV superinfection should be considered in all patients presenting with a severe IBD exacerbation, especially those who are refractory to steroids and immunosuppressives. Treatment involves anti-viral therapy, mainly ganciclovir, and withdrawal of immunosuppressive agents. This leads to improvement of underlying IBD in most patients, and can often avoid, or at least delay, the need for surgical intervention.
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of diabetes mellitus; 1 each of thrombophlebitis, disseminated intravascular coagulation, and deep vein thrombosis; and 1 of osteonecrosis in a patient previously treated with conventional systemic corticosteroids. Conclusions: Based on more than 60 million treatment days, the frequency of reported non-serious and serious AEs following budesonide capsule treatment was low. These results support the findings from both short-and longterm clinical studies demonstrating that budesonide capsules are generally safe and well tolerated for the treatment of mild-to-moderate CD. Results: 113 pts with dysplasia were evaluated of which 102 (90%) had UC and 5 (4%) had CD and 6 (6%) had indeterminate colitis. 53/102 (52%) of UC pts had inadequately documented colonoscopy or incomplete data and were thus excluded from our analysis. The remaining 49/102 (48%) served as our study cohort, Demographics: mean age-58.2 yrs (median 62 yrs, IQR 46-73 yrs); 32/49 (65%)-males; Disease Extent-pancolitis (29/49-59%), left sided (8/49-16%), proctitis (12/49-25%). 45/49 (92%) of pts who had visually detectable lesions at colonoscopy had dysplasia in these lesions. The total number of lesions detected in these 49 colonoscopies were 62; of which 47 (76%) were polyps (5 were described as pseudopolyps), 11 (18%) had suspicious areas of ulceration, 3 (5%) were areas of nodularity and 1 (1%) strictures. Thus, 57 dysplastic lesions in 62 suspected areas (92.0%) in 49 pts (mean dysplastic lesion 1.16/pt). Amongst 57 dysplastic lesions 33 (58%) were polypoid (25-LGD, 76%; 8 HGD, 24%) and 24 (42%) were flat lesions (17-LGD, 71%; 8-HGD, 29%). Conclusions: Dysplasia in UC is endoscopically visible in the majority of pts in undergoing surveillance colonoscopy. Our findings do not preclude the need to perform random surveillance biopsies but suggest that attention should be directed to macroscopically visible lesions when performing surveillance colonoscopy. Further prospective trials are merited to validate our observations.
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